These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 3875605)

  • 41. [Antibacterial activity of sulopenem, a new parenteral penem antibiotic].
    Inoue E; Komoto E; Taniyama Y; Mitsuhashi S
    Jpn J Antibiot; 1996 Apr; 49(4):338-51. PubMed ID: 8786625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The activity and beta-lactamase stability of cefotetan compared to other beta-lactam antibiotics.
    Neu HC; Chin NX
    Chemioterapia; 1985 Aug; 4(4):271-7. PubMed ID: 3876887
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Incidence of strains producing plasmid determined beta-lactamases among carbenicillin resistant Pseudomonas aeruginosa.
    Tirado M; Roy C; Segura C; Reig R; Hermida M; Foz A
    J Antimicrob Chemother; 1986 Oct; 18(4):453-8. PubMed ID: 3095304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Restoration of antibacterial activity of beta-lactams by epigallocatechin gallate against beta-lactamase-producing species depending on location of beta-lactamase.
    Zhao WH; Asano N; Hu ZQ; Shimamura T
    J Pharm Pharmacol; 2003 Jun; 55(6):735-40. PubMed ID: 12841932
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In-vitro evaluation of ampicillin/brobactam and comparison with other beta-lactam antibiotics.
    Melchior NH; Keiding J
    J Antimicrob Chemother; 1991 Jan; 27(1):29-40. PubMed ID: 1646779
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beta-lactam antibiotics and beta-lactamases: two sides of a continuing story.
    Richmond MH
    Rev Infect Dis; 1979; 1(1):30-8. PubMed ID: 400938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.
    Neu HC
    Am J Med; 1985 Nov; 79(5B):2-12. PubMed ID: 3907341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Sensitivity of Pseudomonas aeruginosa to beta-lactam antibiotics and effects of beta-lactamases].
    Avril JL; Cayla AM; Guist'hau O; Moillo-Batt A
    Pathol Biol (Paris); 1983 Jun; 31(6):471-5. PubMed ID: 6410345
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resistance of Pseudomonas species to beta-lactam antibiotics.
    Bidwell JL; Reeves DS
    Scand J Infect Dis Suppl; 1981; 29():20-6. PubMed ID: 7031863
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro activity of faropenem against beta-lactamase producing clinical isolates].
    Nishiyama T; Matsuzaki K; Koyama H; Saika T; Hasegawa M; Kobayashi I
    Jpn J Antibiot; 2000 Mar; 53(3):179-83. PubMed ID: 10834149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beta-lactamase stability and in vitro activity of aztreonam, with a comparison to 9 other beta-lactam antibiotics and gentamicin.
    Friis H; Prag J; Togsverd E; Benson MW
    Chemotherapy; 1986; 32(4):329-35. PubMed ID: 3488177
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinical and laboratory significance of inducible beta-lactamases].
    Bedenić B; Zagar Z
    Lijec Vjesn; 1995; 117(9-10):249-53. PubMed ID: 8643019
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative in-vitro activity of Sch 34343, imipenem, cefpirome and cefotaxime.
    Bauernfeind A
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():155-64. PubMed ID: 3897170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative relationship between sensitivity to beta-lactam antibiotics and beta-lactamase production in gram-negative bacteria--I. Steady-state treatment.
    Frère JM
    Biochem Pharmacol; 1989 May; 38(9):1415-26. PubMed ID: 2785796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combined antibacterial activity of amoxicillin with clavulanic acid against ampicillin-resistant strains.
    Matsuura M; Nakazawa H; Hashimoto T; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Jun; 17(6):908-11. PubMed ID: 6967713
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effects on beta-lactam susceptibility of phenotypic induction and genotypic derepression of beta-lactamase synthesis.
    Shannon K; Phillips I
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():15-22. PubMed ID: 3102451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microbiological properties of sulbactam combined with ampicillin.
    Barba D; Galante D; Esposito S; Ruffilli MP
    Chemioterapia; 1987 Apr; 6(2):88-94. PubMed ID: 3036381
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods.
    Livermore DM
    Eur J Clin Microbiol; 1987 Aug; 6(4):439-45. PubMed ID: 3311738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In-vitro activity and beta-lactamase stability of Sch 29482, a penem antibiotic. Comparisons with ceftazidime and moxalactam.
    Dornbusch K; Adamsson L; Gezelius L; Hallander H
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():113-21. PubMed ID: 6460739
    [No Abstract]   [Full Text] [Related]  

  • 60. The activity of Sch 29482 against type b Haemophilus influenzae lacking or possessing detectable beta-lactamase activity.
    Wong K; Roberts MC; Smith AL
    J Antimicrob Chemother; 1982 Feb; 9 Suppl C():163-70. PubMed ID: 6977529
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.